Clinical Trial Update: Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease [NA]

View source ↗

Summary

AstraZeneca is evaluating palivizumab for prevention of severe respiratory syncytial virus disease in high-risk children. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Synagis (palivizumab)

Snippet

Sponsor: AstraZeneca | Conditions: Respiratory Syncytial Virus (RSV) | NA | Status: RECRUITING